SpinalSurgeryNews - 25 June 2025 Dr. Denis Dufrane co-founded Novadip in 2013 and joined the company as Chief Scientific Officer in 2015 before being appointed CEO. Prior to joining Novadip on a full-time basis, Dr. Dufrane was head of both the Musculoskeletal Tissue...
At 12 months, 100% of participants with distal radius fractures treated in trial with NVDX3, an allogenic stem-cell derived bone graft material, demonstrated durable bone union No adverse events related to NVDX3 observed A phase 2b/3 trial in 2-level cervical spine...
Novadip is a clinical-stage company developing breakthrough stem cell-based tissue regeneration therapies to accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment.
Article de l'Echo - Catarina Letor. La Belgique est championne européenne des dépenses en R&D, mais ses résultats sont mitigés. En 2022, malgré des investissements colossaux, seules 10 spin-offs sont sorties des cinq universités de recherche que compte la...
Article du Trends Tendances - Canal Z La Belgique est un des leaders mondiaux dans le secteur des biotech. Mais trouver des financements n’est pas simple. C’est là que la Banque européenne d’investissement peut entrer en jeu, car l’investissement dans les biotech est...
Article du Trends Tendances - Canal Z La Banque européenne d’investissement accorde 18 millions d’euros à Novadip et € 20 millions à The Akkermansia Company. Ce financement à risque est rendu possible par une garantie de la Commission européenne.
Merci Le Forem, Sylvia Chauvier et aptaskil pour l’organisation de notre Afterwork du 6 juin et merci aux nombreux candidats qui y ont participé ! Nous espérons rencontrer de nouveaux collègues prochainement.
A preview of the top trends on the minds of industry and market leaders for the new year.
Patients that require reconstruction of large sections of bone and skin currently have limited options. With its 3M3 platform, Novadip Biosciences hopes to change patient lives by offering new regenerative medicine treatment options for patients...
Denis Dufrane, M.D., Ph.D. wanted to skip the formal part. An accomplished academic and clinician, he’d spent 15 years at the Université Catholique de Louvain—where he’d earned his M.D. and his Ph.D. in biomedical sciences with a concentration on cell...
Novadip Biosciences – a company developing regenerative tissue products to accelerate large bone defect healing – announced positive data from its phase 1/2 clinical trial.
Novadip Biosciences announced positive data from its Phase I/II clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003, in patients with severe bone non-union (BNU) of the lower limb following trauma.
Novadip Biosciences SA has announced positive data from its phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003.
Novadip annonce des résultats positifs de l'essai clinique de son traitement expérimental de guérison de fractures osseuses.
Novadip Biosciences recently received an infusion of €40 million (~USD $40 million) in investments, increasing its total funding to €88 million. The Belgium-based company will use the capital to develop a new class of adipose-derived stem cell (ASC) tissue...
Novadip Biosciences raised an additional €40 million (~USD $40 million) in a Series B equity round and non-dilutive funding. This brings the company’s total funding to €88 million, to date.
Tissue regeneration biotech Novadip Biosciences raised €40 million. The cash will go toward two clinical-stage programs: an allogeneic bone union therapeutic called NVD-X3 and NVD-003, an autologous bone engraftment product. The cash breaks down to €24 million in...
Novadip Biosciences, a Belgium-based biopharmaceutical company, has raised an additional €40 million in a Series B equity round and non-dilutive funding.
The clinical-stage biopharma company is developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment.
Novadip Biosciences, a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has raised an additional EUR 40 million ($39.1 million) in a Series B...
Novadip SA raised €19 million (US$22.1 million) in a first close of a series B round to progress its autologous bone regeneration therapy, NVD-003, on either side of the Atlantic. The company is also working on an allogeneic regenerative approach, which is still...
Read this article about Novadip published on the website of biopharmadealmakers.
Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Therapeutics as president and CEO for the past eight years.